NCT07527156 Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure
| NCT ID | NCT07527156 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Institute for Clinical and Experimental Medicine |
| Condition | Acute Heart Failure (AHF) |
| Study Type | INTERVENTIONAL |
| Enrollment | 12 participants |
| Start Date | 2026-04-04 |
| Primary Completion | 2027-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 12 participants in total. It began in 2026-04-04 with a primary completion date of 2027-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will evaluate the feasibility and safety of achieving therapeutic concentrations of beta-hydroxybutyrate using continuous infusion of D-beta-hydroxybutyrate monoester administered via a nasogastric tube in patients with acutely decompensated heart failure with reduced left ventricular ejection fraction.
Eligibility Criteria
Inclusion Criteria: * LVEF \<35% * Acute heart failure with low cardiac output syndrome or cardiogenic shock Exclusion Criteria: * Severe liver failure * Severe acidosis * Inability to insert nasogastric tube * Gastric paralysis / ileus * Repeated vomiting * Severe hypokalemia
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07527156 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Heart Failure (AHF). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07527156 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07527156 currently recruiting?
Yes, NCT07527156 is actively recruiting participants. Contact the research team at marek.sramko@ikem.cz for enrollment information.
Where is the NCT07527156 trial being conducted?
This trial is being conducted at Prague, Czechia.
Who is sponsoring the NCT07527156 clinical trial?
NCT07527156 is sponsored by Institute for Clinical and Experimental Medicine. The trial plans to enroll 12 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.